Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline drugs market research report outlays comprehensive information on the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. It also reviews key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics development with respective active and dormant or discontinued projects. The report also covers products from therapy areas such as central nervous system, undisclosed, and women’s health which includes indications of Anxiety Disorders, Post-Traumatic Stress Disorder (PTSD), Alzheimer’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Dravet Syndrome (Severe Myoclonic Epilepsy Of Infancy), Drug-Induced Dyskinesia, Infantile Spasm (West Syndrome), Lennox-Gastaut Syndrome, Opium (Opioid) Addiction, Parkinson’s Disease, Post-Partum Depression (Maternal Depression / Postnatal Depression), Rett Syndrome, Status Epilepticus, and Unspecified and Visceral Pain.
GPRC1G Pipeline Drugs Market by Key Therapy Areas
The key therapy areas in the GPRC1G pipeline drugs market are central nervous system, undisclosed, and women’s health.
GPRC1G Pipeline Drugs Market, by Therapy Areas
For more therapy area insights, download a free report sample
Key Mechanism of Actions in the GPRC1G Pipeline Drugs Market
The key mechanism of actions in the GPRC1G pipeline drugs market are Metabotropic Glutamate Receptor 7 Agonist and Metabotropic Glutamate Receptor 7 Antagonist.
Key Routes of Administration in the GPRC1G Pipeline Drugs Market
The key routes of administration in the GPRC1G pipeline drugs market are oral and intravenous.
GPRC1G Pipeline Drugs Market, by Routes of Administration
For more route of administration insights, download a free report sample
Key Molecule Types in the GPRC1G Pipeline Drugs Market
The key molecule type in the GPRC1G pipeline drugs market is small molecule.
Key Companies in the GPRC1G Pipeline Drugs Market
The key companies in the GPRC1G pipeline drugs market are Addex Therapeutics Ltd, Bio-Pharm Solutions Co Ltd, Domain Therapeutics SA, and Nobias Therapeutics Inc.
GPRC1G Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Metabotropic Glutamate Receptor 7 Pipeline Drugs Market Report Overview
Key Therapy Areas | Central Nervous System, Undisclosed, and Women’s Health |
Key Mechanism of Actions | Metabotropic Glutamate Receptor 7 Agonist and Metabotropic Glutamate Receptor 7 Antagonist |
Key Routes of Administration | Oral and Intravenous |
Key Molecule Types | Small Molecule |
Key Companies | Addex Therapeutics Ltd, Bio-Pharm Solutions Co Ltd, Domain Therapeutics SA, and Nobias Therapeutics Inc |
Scope
This report provides:
- A snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7).
- Reviews of targeted therapeutics for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on various stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Reviews of key players involved in Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) therapeutics and enlists all their major and minor projects.
- Assessment of Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA), and molecule type.
- Summarization of all the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) targeted therapeutics.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7).
- Identify the use of drugs for target identification and drug repurposing.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding the Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) development landscape.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas of the GPRC1G pipeline drugs market?
The key therapy areas in the GPRC1G pipeline drugs market are central nervous system, undisclosed, and women’s health.
-
What are the key mechanism of actions in the GPRC1G pipeline drugs market?
The key mechanism of actions in the GPRC1G pipeline drugs market are Metabotropic Glutamate Receptor 7 Agonist and Metabotropic Glutamate Receptor 7 Antagonist.
-
What are the key routes of administration in the GPRC1G pipeline drugs market?
The key routes of administration in the GPRC1G pipeline drugs market are oral and intravenous.
-
What are the key molecule types in the GPRC1G pipeline drugs market?
The molecule type in the GPRC1G pipeline drugs market is small molecule.
-
Which are the key companies in the GPRC1G pipeline drugs market?
The key companies in the GPRC1G pipeline drugs market are Addex Therapeutics Ltd, Bio-Pharm Solutions Co Ltd, Domain Therapeutics SA, and Nobias Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.